Clinical Trials · NCT00035984
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 734
- Start date
- May 2002
- Locations
- 100 sites, United States
- Primary endpoint
- Change in HbA1c from Baseline to Week 30